Calluna Pharma is an Oslo-based clinical-stage biotech building first-in-class antibodies that switch off the upstream signals driving inflammation and fibrosis. Formed in 2024 from the merger of Oxitope Pharma and Arxx Therapeutics and backed by a EUR 75 million Series A, the company targets damage-associated molecular patterns (DAMPs) such as S100A4 to halt diseases like idiopathic pulmonary fibrosis at their root rather than managing symptoms.
Mark Gaffney is the Chief Executive Officer and Board member of Calluna Pharma, an Oslo-based clinical-stage biopharma chasing inflammatory and fibrotic disease by tuning the body's innate immune system. A mechanical engineer turned lawyer turned dealmaker, he spent two decades building and selling biotechs - Oxular went to Regeneron, Vedere Bio to Novartis - before taking the helm of a company born from the merger of Oxitope Pharma and Arxx Therapeutics and freshly backed by a 75 million euro Series A.
Thomas C. Holst is a Norwegian-American business architect, investor, and entrepreneur who built Huddly - a Norwegian deep tech computer vision company - from a four-person startup into a publicly listed global enterprise with offices in Oslo, Palo Alto, London, Austin, Washington, and Bangalore. With a career spanning management consulting (A.T. Kearney), private equity (Reiten & Co, Orkla Finance), and deep tech venture building, he has collaborated with Amazon, Intel, Microsoft, Google, and Zoom. After departing Huddly, he co-founded Northscaler - a B2B tech venture firm connecting Nordic startups with global corporations - and became a Partner at ICON Asset Management AG in 2024.
Robin Wigglesworth is the editor of FT Alphaville, the Financial Times' irreverent and free-to-read finance blog, which he runs from Oslo, Norway. A former Bloomberg Nordic economics correspondent turned Gulf war reporter turned global finance authority, Wigglesworth has carved out a rare niche: making the most technically forbidding corners of finance genuinely fun to read. His 2021 book Trillions - a definitive history of the index fund - became one of the FT's best books of the year, and his forthcoming A Fabulous Debt (September 2026) promises a sweeping history of the bond market. He is equal parts serious financial scholar and gleeful financial provocateur.